FDA Accountability for Public Safety Act

S 603 requires the FDA Commissioner to personally approve opioid drugs against an advisory committee's recommendation (instead of delegating the decision), directly affecting opioid drug approvals. It mandates detailed reports to Congress explaining the safety evidence supporting such approvals and disclosing any potential conflicts of interest involving FDA officials. The bill also prohibits marketing the drug until these reports are submitted to Congress. These provisions aim to increase transparency and accountability in FDA decisions on opioid medications.